TY - JOUR
T1 - Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine
AU - Akerman, Simon
AU - Romero-Reyes, Marcela
N1 - Publisher Copyright:
© 2013 Informa UK Ltd.
PY - 2013
Y1 - 2013
N2 - Migraine is one of the most severe and debilitating brain disorders. Most scientists accept that it involves activation and sensitization of the trigeminovascular system, which includes the sensory peripheral projections to the pain-producing dura mater, and a central projection to the trigeminal nucleus caudalis and its cervical extension, the trigeminocervical complex (TCC). The development of the anti-migraine therapeutics, triptans-5-HT1B/1D receptor agonists, had originally targeted the craniovasculature to exert therapeutic effects, and this locus of action seemed to predict efficacy in the clinic. However, subsequent development of novel targets, using the same strategy failed to replicate this early success and as a consequence central mechanisms of action away from the dural vasculature were thought to be responsible for these therapeutic effects. Coupled to this, migraine has been hypothesized to involve a dysfunction of areas of the brainstem and diencephalon, which seem to mediate the activation, or perception of activation, of the trigeminovascular system as well as sensitization of neuronal pathways that drive trigeminovascular activation. Therefore, drug targets that act in the brain, specifically on the central component of the trigeminovascular system, the TCC, would seem to be ideally placed to modulate this nociceptive pathway and relieve migraine, but particularly the headache phase. This review will discuss how the TCC, rather than other more craniovascular sites, may be the anatomical target of some of the current and emerging therapies to relieve migraine symptoms, and why this should prove to be a fruitful area for drug development for the treatment of migraine.
AB - Migraine is one of the most severe and debilitating brain disorders. Most scientists accept that it involves activation and sensitization of the trigeminovascular system, which includes the sensory peripheral projections to the pain-producing dura mater, and a central projection to the trigeminal nucleus caudalis and its cervical extension, the trigeminocervical complex (TCC). The development of the anti-migraine therapeutics, triptans-5-HT1B/1D receptor agonists, had originally targeted the craniovasculature to exert therapeutic effects, and this locus of action seemed to predict efficacy in the clinic. However, subsequent development of novel targets, using the same strategy failed to replicate this early success and as a consequence central mechanisms of action away from the dural vasculature were thought to be responsible for these therapeutic effects. Coupled to this, migraine has been hypothesized to involve a dysfunction of areas of the brainstem and diencephalon, which seem to mediate the activation, or perception of activation, of the trigeminovascular system as well as sensitization of neuronal pathways that drive trigeminovascular activation. Therefore, drug targets that act in the brain, specifically on the central component of the trigeminovascular system, the TCC, would seem to be ideally placed to modulate this nociceptive pathway and relieve migraine, but particularly the headache phase. This review will discuss how the TCC, rather than other more craniovascular sites, may be the anatomical target of some of the current and emerging therapies to relieve migraine symptoms, and why this should prove to be a fruitful area for drug development for the treatment of migraine.
KW - Brainstem
KW - CGRP receptor antagonists
KW - Migraine
KW - NSAIDs
KW - Preventives
KW - Trigeminocervical complex
KW - Triptans
UR - http://www.scopus.com/inward/record.url?scp=84895191259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895191259&partnerID=8YFLogxK
U2 - 10.1586/14737175.2013.827472
DO - 10.1586/14737175.2013.827472
M3 - Review article
C2 - 23952299
AN - SCOPUS:84895191259
SN - 1473-7175
VL - 13
SP - 1041
EP - 1059
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 9
ER -